NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $0.84 +0.00 (+0.41%) As of 03:13 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainSEC Filings About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCLI alerts:Sign Up Key Stats Today's Range$0.77▼$0.8450-Day Range$0.78▼$1.4152-Week Range$0.46▼$1.69Volume21,143 shsAverage Volume19,826 shsMarket Capitalization$11.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BrainStorm Cell Therapeutics Inc. is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s proprietary NurOwn platform uses a patient’s own bone marrow-derived mesenchymal stem cells, which are expanded and induced to secrete neurotrophic factors and other proteins intended to support the survival and function of nerve cells. BrainStorm’s lead candidate, NurOwn, has primarily been studied as a potential treatment for amyotrophic lateral sclerosis (ALS). The company has also investigated the platform in other disorders, including progressive multiple sclerosis and Parkinson’s disease. Its activities include clinical development, manufacturing-process development, regulatory work and research into additional applications for its cellular technology. Founded in Israel, BrainStorm Cell Therapeutics has conducted development activities in the United States and internationally through clinical studies and regulatory interactions. The company continues to focus on advancing its NurOwn platform and evaluating potential therapies for serious neurological conditions for which treatment options remain limited.AI Generated. May Contain Errors. Read More Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCLI Stock News HeadlinesBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Break Above 200-Day Moving Average - Here's What HappenedOctober 9, 2026 | americanbankingnews.comBrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsAugust 24, 2026 | prnewswire.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 14 at 1:00 AM | Brownstone Research (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Brainstorm Cell Therapeutics (OtherBCLI) and Edwards Lifesciences (EW)August 20, 2026 | theglobeandmail.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deBrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14, 2026 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanJuly 28, 2026 | finanznachrichten.deBrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanJuly 28, 2026 | prnewswire.comSee More Headlines BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $0.5530 at the beginning of the year. Since then, BCLI stock has increased by 51.0% and is now trading at $0.8350. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its earnings results on Friday, August, 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.06. When did Brainstorm Cell Therapeutics' stock split? Brainstorm Cell Therapeutics shares reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Plug Power (PLUG), GE Aerospace (GE), AbbVie (ABBV), Alibaba Group (BABA) and Bank of America (BAC). Company Calendar Last Earnings8/14/2026Today10/14/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCLI CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year Founded2004Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.62 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-519.50% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.61Miscellaneous Outstanding Shares14,259,000Free Float8,742,000Market Cap$11.91 million OptionableOptionable Beta0.28 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BCLI) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
